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 Abstract 
Aims: To determine whether cardiac autonomic dysfunction represents a risk factor for 
diabetic retinopathy (DR) development and progression in persons with type 1 diabetes 
mellitus (T1DM). 
Methods: The study comprised 154 normoalbuminuric persons with T1DM divided into two 
groups according to the DR presence: one with and another without DR. Cardiovascular 
autonomic functioning was accessed by conventional and spectral data analysis. Student’s t-test 
and Fischer’s exact test were used to access between group differences. Cox’s proportional hazards 
regression analysis was used to examine the baseline variables predictive for development or 
progression of NPR 18 months after. 
Results: The group with DR had longer disease duration compared to the group witout DR 
(20 vrs 11.5 years, p<0.001), heart rate coefficient of variation (HRV-CV) at rest and during 
deep breathing, as well as its vagal nerve mediated modulation, were lower in participants 
with DR (p=0.001; 0.004 and <0.001, respectively). No difference in glycaemic control, lipid 
status or hypertension rate was observed. Twenty-one (13.36%) participants developed non 
proliferative DR or progressed to proliferative DR. For each increase in the HRV-CV of 1%, the 
18 months risk from retinal deterioration was reduced by 33.4% and by 12.7% for the same HRV-CV 
increase during deep breathing while the increase of parasympathetic nerve activity output of 1 ms
2
 
results in 8.6% DR risk reduction. 
Conclusions: This study provides evidence that DR should not be considered merely a 
metabolic control manifestation and that HRV-CV might be the top predictor of retinal 
deterioration in normoabuminuric persons with T1DM.  
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1. Introduction 
Diabetic retinopathy (DR) is the most frequent cause of visual impairment and legal blindness 
among adults with type 1 diabetes mellitus (T1DM) [1]. The pathogenesis of its development 
and progression is not completely understood. To date, dysglycaemia, elevated blood pres-
sure, dyslipidaemia and longer diabetes duration are the most pronounced risk factors for DR 
development and progression [2-4].  Diabetic kidney disease, often accompanied with urine 
albumin excretion above 30 mg/24 hours coincides with DR [5, 6]. Moreover, the structural 
changes in the kidney which include glomerular basement membrane thickening, micro aneu-
rysm formation and mesangial nodule formation represent the similar small histological find-
ing seen in DR [7, 8].  
Cardiovascular autonomic neuropathy (CAN) is defined as impairment of autonomic control 
of the cardiovascular system in the setting of diabetes after exclusion of other causes with 
prevalence ranging from 16-20% among persons with diabetes [9]. There is a well established 
causative role of CAN in diabetic kidney disease development and progression in persons 
with T1DM [10, 11] while an association between CAN and DR has been reported in several 
cross-sectional studies [6, 12-14]. Clinical symptoms of CAN: resting tachycardia and a fixed 
heart rate represent the characteristic of structural vagal nerve impairment and may not appear 
until long after diabetes onset [9]. Subclinical CAN however represents functional abnormali-
ties of the autonomic nervous system, i.e. the imbalance between the sympathetic and para-
sympathetic nervous system that can be discerned by using spectral analysis of heart rate vari-
ability (HRV) [15, 16, 17].  
Spectral analysis involves decomposing the series of sequential R-R intervals into a sum of 
sinusoidal functions of different amplitudes and frequencies by several possible mathematical 
approaches, such as fast Fourier transformation [18]. The result (power spectrum) reflects the 
amplitude of the HRV present at different oscillation frequencies. The power spectrum of 
HRV has been shown to consist of two major peaks: low-frequency (LF) component which 
represents the parasympathetic/vagal nerve contribution to HRV-CV at rest and high-
frequency (HF) component which reflects parasympathetic contribution to HRV-CV during in 
relation to respiration. 
It would be of a special interest to investigate whether early, subclinical CAN contributes to 
the risk of DR and whether it might represent an independent risk factor for its development 
and progression in normoabuminuric type 1 diabetic (T1DM).  We aimed to determine 
whether CAN assessment accompanied by detailed spectral analysis might serve as a practical 
tool to identify a group of T1DM patients with a higher risk for retinal deterioration. 
 
2. Materials and Methods 
2.1 Study population 
One hundred fifty four randomly selected normoalbuminuric persons with T1DM  referred to 
tertiary care specialist between January 2011 and December 2014 were included in the study 
after informed consent was obtained. T1DM was diagnosed according to World Health 
Organization (WHO) criteria (< 35 years at the age of onset of diabetes, a previous episode of 
ketoacidosis or documented ketonuria, positive autoantibodies and permanent insulin 
treatment initiated within 1 year of diagnosis) [19]. Eligible participants were at least 18 years 
old, minimum duration of T1DM of 1 year, no medical history of cardiovascular diseases or 
electrocardiogram (ECG) evidence of ischemic heart disease, absence of any systemic disease 
and absence of any infections in the previous month. Urine albumin excretion (UAE) was 
measured from at least two 24-h urine samples and determined as the mean of 24-h urine 
collections in order to minimize variability. Normoalbuminuria was defined as a UAE<30 
mg/24h [20]. Fasting venous blood samples were collected for the determination of a glycated 
haemoglobin (HbA1c, %, reference interval 3.5–5.7), C-reactive protein (CRP), serum 
creatinine in order to exclude a wide range of disorders that might affect the study results. 
HbA1c was measured spectrophotometrically by turbidimetric immuno-inhibition (Olympus 
AU600, Beckman-Coulter, USA). 
Blood pressure was measured in the sitting position with a mercury sphygmomanometer with 
a cuff appropriate to the length and circumference of the arm after a resting period of 10 
minutes and expressed in mmHg. Patients taking blood pressure medications or with blood 
pressure >140/90 mmHg were considered to have hypertension. 
Participants were re-examined after 18 months to update their glycaemic control, UAE and 
retinopathy status. The study protocol complied with the Declaration of Helsinki as well as 
local institutional guidelines. 
 
2.2 Data acquisition  
Complete eye examination included best corrected visual acuity (BCVA), Goldmann 
applanation tonometry, slit lamp biomicroscopy of the anterior eye segment, binocular 
indirect slit lamp fundoscopy and fundus photography after mydriasis with eye drops 
containing 0.5 % tropicamide and 5 % phenylephrine. Color fundus photographs of two fields 
(macular field, disc/nasal field) of both eyes were taken with a suitable 45° fundus camera 
(VISUCAM, Zeiss) according to the EURODIAB retinal photography methodology [21]. 
Macular field: positioned in such a way that the exact centre of the optic disc laid at the nasal 
end of the horizontal meridian of the field view. Disc/nasal field: such that the optic disc was 
positioned one disc-diameter in from the temporal edge of the field, on the horizontal 
meridian. EURODIAB classification scheme was used because it uses two-field 45° fundus 
photography and standard photographs to grade retinal lesions. In each person the "worse" 
eye was graded for retinopathy using fundus photographs. 
Autonomic nervous system testing was carried out on VAGUS 2100 (Sigma Medizin Technik, 
Thum, Germany) Test conditions was standardized as suggested by Spallone et al. (2011) [17] 
as follows: testing was conducted between 9-12 a.m., at least 2 hours after a light breakfast, a 
tested subject did not consume coffee, black tea or nicotine and blood glucose was checked 
prior to testing. Three disposable, self-adhesive ECG electrodes were applied to the chest with 
adhesive tape. Standard battery of cardiovascular tests to confirm diabetic autonomic 
dysfunction included: the coefficient of variation (CV) of RR intervals at rest indicating HRV 
at rest (HRV-CV), HRV-CV during deep breathing (dbHRV-CV), Valsalva manoeuvre in order 
to obtain Valsalva ratio: the ratio of the highest RR interval after the manoeuvre to the loveat 
during the manoeuvre, ), active orthostatic test, blood pressure response to standing, deep 
breathing E / I ratio (dbE/I) and 30:15 ratio [22].. Although there are no unanimous criteria for 
CAN diagnosis, the presence of abnormalities in two or three abnormal results among 
mentioned autonomic tests is recommended for cardiac autonomic neuropathy diagnosis 17, 
23]. 
Furthermore, as suggested by Barlund et al. (2009) [24], from the original data of RR interval 
series, using the fast Fourier transformation, the computer system obtained the power in the 
low frequency (LF) (0.04-0.15 Hz) and high-frequency (HF) (0.15-0.40 Hz). Normalised units 
of the LF and HF bands were calculated as follows: nLF=LF power/(LF+HF powers) and 
nHF=HF power/(LF+HF power) where n stands for normalised and HF for high and LF for 
low-frequency power. 
 
 
 
2.3 Statistical analysis 
The data distribution was assessed by Shapiro-Wilk test. All the continuous variables were 
log-transformed in order to reduce the skew, and reported as mean values and 95%CI of 
means or standard deviation (SD), whereas categorical variables were reported as numbers 
and percentages. The differences between two study groups baseline characteristics were 
tested by Student’s t-test while the categorical variables were analysed by the Fischer’s exact 
test. 
Cox’s proportional hazards multiple regression analyses was used to examine the baseline 
variables predictive for development or progression of non proliferative DR, taking in account 
of potential confounders and pre-existing retinopathy status. Results are described as relative 
risk (hazard ratio). A p value of less than 0.05 was considered significant. 
3. Results 
The mean age of study population was 37.5 years with 14 years of diabetes duration. Seventy 
four participants (48.05%) were male. CAN was established in 14 (9.09%) of them, however, 
non of the patients had pathological result of Valsalva manoeuvre nor orthostatic hypotension, 
as expected. The prevalence of non proliferative DR was 30.51% (N=47). There were no 
patients with the history of laser photocoagulation due to severe non proliferative, 
proliferative DR or macular oedema.  
The mean UAE was 11.45 (95% CI 10.43-12.47 mg/24h) at the study beginning. Forty six 
participants (29.87%) were smokers, 58 (37.66%) were taking the nephroprotective dose of 
trandolaprilum (0.5 mg/day). The results of cardiovascular autonomic function assessment in 
47 T1DM persons with non proliferative DR and 107 free of DR are given in Table 1. Persons 
with non proliferative DR showed significantly lower HRV-CV at rest and dbHRV-CV when 
compared to group of persons without DR. We also observed a significant attenuation for both 
LF and HF bands in the group with non proliferative DR indicating that they have had lower 
parasympathetic or higher sympathetic nerve activity. calculate the LF/HF ratio that is 
considered an expression of the sympathovagal balance Although the in-between group 
duration of diabetes was significantly different, long-term glycaemic control assessed by 
HbA1c was similar.  
Additionally, it did not show the significant change until the study end (7.0 (6.6-7.2) vs 6.9 
(5.1-7.5) for all, p=0.566). Six (3.89%) participants developed albuminuria (UAE 29.87 
(10.59-37.54) mg/24h for all) during 18 months follow up period while 21 (13.36%) 
developed non proliferative DR or progressed from non proliferative DR to proliferative DR. 
Retinal status deterioration was independent of the baseline retinal status (Figure 1.). The 
HRV-CV,  dbHRV-CV and LF power showed inverse correlation with the disease duration 
(r=-0.633, p=0.043; r=-0441, p=0.012 and r=-0.391, p=0.040, respectively).  
The Cox regression model (Table 2.) revealed that baseline HRV-CV and dbHRV-CV reduce 
the risk of DR incidence and progression. For each increase in the HRV-CV of 1%, the 18 
months risk from retinal deterioration is reduced by 33.4% and by 12.7% for the same HRV-
CV increase during deep breathing. In addition, increase in LF band of 1 ms
2 
results in 8.6% 
DR risk reduction in the same period of time. 
4. Discussion 
In the present study a battery of non invasive cardiovascular autonomic function tests 
proposed by Ewing [23] and a power spectral analysis of HRV-CV in 154 strictly 
normotensive, normoalbuminuric, metabolically adequately regulated T1DM was performed 
in order to elucidate the possible pathogenic role of autonomic dysfunction in DR 
development and progression during 18 months of follow-up in.  The possible predictive 
association between lower spectral indices of HRV that might derive from both 
parasympathetic impairment and sympathetic activation with the DR development and 
progression was identified. This relation persisted after adjusting for age, gender, disease 
duration, HbA1c, ACE inhibitor use smoking status, UAE, total daily insulin dose, blood 
pressure and CAN presence which are already described as risk factors linked to DR 
pathogenesis [1, 5-8].  
The manifest CAN with blunted parasympathetic activity was reported in persons with 
albuminuria [4, 7, 8], non proliferative DR [6] and proliferative DR [12]. However, there are 
only few studies conducted in order to establish the potential causative role of early, 
asymptomatic autonomic nervous system functional disturbances with changes in retinal 
microarchitecture [16, 26]. The small proportion of abnormalities obtained from the 
conventional autonomic nervous system tests compared to the differences in the spectral data 
indicates that we did access the group of patients with autonomic nervous system dysfunction 
[24] and that the presence of 14 (9.09%) with CAN diagnosis did not affect the final results.  
It is well known that chronic hyperglycaemia promotes progressive dysfunction of autonomic 
nervous system in a manner that accompanies peripheral neuropathy development, i.e., 
beginning distally and progressing proximally. The vagus nerve, which is the longest 
autonomic nerve, mediates about 75% of all parasympathetic activity. Because neuropathy is 
seen first in the longest nerve fibres, the earliest manifestations of autonomic neuropathy in 
diabetes tend to be associated with parasympathetic denervation. Our data and those of others 
[27, 28] confirm that there is a compensatory increase in the cardiac sympathetic tone in the 
early phase of CAN. Since heart rate represents a balance between sympathetic and 
parasympathetic part of the autonomic nervous system activity, its alterations represent the 
earliest manifestation of disruption in autonomic nervous functioning, i.e. autonomic 
neuropathy. Moreover, CAN could be a manifestation of the disease duration and severity 
since it is more frequent in the patients with longer diabetes duration and oftenly associated 
with other microvascular complications [27-29]. 
Although the correlation between CAN and DR in T1DM has been reported [6] and recent 
study by Huang (2016) [29] suggests that DR is the most significant risk factor predictive of 
the presence of CAN in 174 patients with type 2 diabetes., its implications in the 
patophysiological mechanism of  retinal damage remains unresolved, especially because it has 
not been confirmed whether retinal vessels possess any sympathetic innervation [30]. The 
direct effect of autonomic nervous system on retinal blood flow is therefore dubious which 
brings to focus the proposed indirect mechanism through systemic hemodynamic changes. 
The pathophysiology of DR comprises a complex of hemodynamic disorders leading to 
endothelial dysfunction, intimal denudation, retinopathy induction and deterioration. The 
increase in symphatetic tone as observed in our study leads to systemic disbalance between 
vasoconstriction and vasodilatation [31] which consequently leads to blood pressure alteration 
and might mediate the association of CAN with DR as previously proposed [6]. More 
important, a possible increased blood pressure load during the night in patients with CAN 
might result in retinal ischemia [4, 6, 31, 32] because autonomic dysfunction may affect 
retinal vessels autoregulation, allowing even small blood pressure elevations to have a 
deterious impact on the retina caused by capillary hypertension, hyperperfusion and a 
consecutive damage.   
Our study has several limitations that should be pointed out: we used the convenience sample 
method, which definitely contributes to the possible bias of the study for example: we do not 
have the complete data on the previous glycaemic control. As far the methodology, we did not 
take into account to precisely monitor breathing during deep breathing tests; it was estimated 
by a performing technician instead. At last, the number of patients with CAN must have had 
impact on the study results. However, we do believe that although we marked a significant 
difference in the disease duration between T1DM persons with DR and those without DR, 
HRV-CV might one of the less recognised factors contributing to  retinal deterioration in 
normoabuminuric T1DM patients. Early and detailed CAN assessment followed by spectral 
analysis of HRV might serve as a practical tool to identify a group of T1DM patients with a 
higher risk for retinal deterioration. 
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